ES2531006T3 - Derivados de benzofurano como moduladores de FXR - Google Patents
Derivados de benzofurano como moduladores de FXR Download PDFInfo
- Publication number
- ES2531006T3 ES2531006T3 ES09731855T ES09731855T ES2531006T3 ES 2531006 T3 ES2531006 T3 ES 2531006T3 ES 09731855 T ES09731855 T ES 09731855T ES 09731855 T ES09731855 T ES 09731855T ES 2531006 T3 ES2531006 T3 ES 2531006T3
- Authority
- ES
- Spain
- Prior art keywords
- benzofuran
- piperazin
- carboxylic acid
- bromo
- benzenesulfonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos seleccionados del grupo - éster terc-butílico del ácido 4-(4-Bromo-2-etoxicarbonil-benzofuran-5-il)-piperazin-1-carboxílico - éster terc-butílico del ácido 4-(4-Bromo-2-carboxi-benzofuran-5-il)-piperazin-1-carboxílico - amida del ácido 5-[4-(3-Metoxi-bencenosulfonil)-piperazin-1-il]-benzofuran-2-carboxílico - amida del ácido 5-[4-(4-Metoxi-bencenosulfonil)-piperazin-1-il]-benzofuran-2-carboxílico - amida del ácido 5-[4-(3-Trifluorometil-bencil)-piperazin-1-il]-benzofuran-2-carboxílico - amida del ácido 5-[4-(3-Cloro-bencil)-piperazin-1-il]-benzofuran-2-carboxílico - amida del ácido 5-[4-(3-Fluoro-benzoil)-piperazin-1-il]-benzofuran-2-carboxílico - amida del ácido 5-[4-(3-Cloro-bencenosulfonil)-piperazin-1-il]-benzofuran-2-carboxílico - amida del ácido 4-Bromo-5-[4-(4-metoxi-bencenosulfonil)-piperazin-1-il]-benzofuran-2-carboxílico - ácido 5-(4-Bencenosulfonil-piperazin-1-il)-benzofuran-2-carboxílico - ácido 4-Bromo-5-[4-(3-fluoro-benzoil)-piperazin-1-il]-benzofuran-2-carboxílico - ácido 4-Bromo-5-[4-(3-cloro-bencenosulfonil)-piperazin-1-il]-benzofuran-2-carboxílico - ácido 4-Bromo-5-[4-(3-fluoro-bencenosulfonil)-piperazin-1-il]-benzofuran-2-carboxílico - ácido 4-Bromo-5-[4-(pirrolidin-1-carbonil)-piperazin-1-il]-benzofuran-2-carboxílico - ácido 4-Bromo-5-[4-(3-cloro-bencil)-piperazin-1-il]-benzofuran-2-carboxílico - éster terc-butílico del ácido 4-(2-Carboxi-benzofuran-5-ilamino)-piperidin-1-carboxílico - éster terc-butílico del ácido 2-[4-(4-Bromo-2-carboxi-benzofuran-5-il)-piperazin-1-carbonil]-pirrolidin-1-carboxílico~ - éster terc-butílico del ácido 4-(4-Cloro-2-etoxicarbonil-benzofuran-5-il)-piperazin-1-carboxílico - éster terc-butílico del ácido 4-(2-Carboxi-4-cloro-benzofuran-5-il)-piperazin-1-carboxílico - ácido 4-Bromo-5-[4-(3-trifluorometil-bencil)-piperazin-1-il]-benzofuran-2-carboxílico - ácido 5-[4-(3-Metoxi-bencenosulfonil)-piperazin-1-il]-benzofuran-2-carboxílico - ácido 4-Bromo-5-[4-(3-metoxi-bencenosulfonil)-piperazin-1-il]-benzofuran-2-carboxílico - ácido 4-Bromo-5-[4-(4-metoxi-bencenosulfonil)-piperazin-1-il]-benzofuran-2-carboxílico - ácido 4-Bromo-5-[4-(pirrolidin-2-carbonil)-piperazin-1-il]-benzofuran-2-carboxílico - ácido 5-[4-(Adamantan-1-carbonil)-piperazin-1-il]-4-bromo-benzofuran-2-carboxílico - ácido 4-Bromo-5-[4-(3-cloro-benzoil)-piperazin-1-il]-benzofuran-2-carboxílico - ácido 4-Bromo-5-[4-(2-fluoro-bencil)-piperazin-1-il]-benzofuran-2-carboxílico - ácido 4-Bromo-5-[4-(3-fluoro-bencil)-piperazin-1-il]-benzofuran-2-carboxílico - ácido 5-(4-Benzoil-piperazin-1-il)-4-bromo-benzofuran-2-carboxílico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08300183A EP2110374A1 (en) | 2008-04-18 | 2008-04-18 | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators |
PCT/EP2009/002297 WO2009127321A1 (en) | 2008-04-18 | 2009-03-30 | Benzofurane, benzothiophene, benzothiazol derivatives as fxr modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2531006T3 true ES2531006T3 (es) | 2015-03-09 |
Family
ID=39769187
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES09731855T Active ES2531006T3 (es) | 2008-04-18 | 2009-03-30 | Derivados de benzofurano como moduladores de FXR |
Country Status (27)
Country | Link |
---|---|
US (1) | US8575161B2 (es) |
EP (2) | EP2110374A1 (es) |
JP (2) | JP5616326B2 (es) |
KR (1) | KR101662853B1 (es) |
CN (1) | CN101990535B (es) |
AR (1) | AR071207A1 (es) |
AU (1) | AU2009238015B2 (es) |
BR (1) | BRPI0911243B8 (es) |
CA (1) | CA2721591C (es) |
CO (1) | CO6311099A2 (es) |
CY (1) | CY1116333T1 (es) |
DK (1) | DK2262785T3 (es) |
EA (1) | EA020454B1 (es) |
EC (1) | ECSP10010615A (es) |
ES (1) | ES2531006T3 (es) |
HK (1) | HK1155741A1 (es) |
HR (1) | HRP20150319T1 (es) |
IL (1) | IL208322A (es) |
MX (1) | MX2010011292A (es) |
MY (1) | MY156530A (es) |
NZ (1) | NZ589327A (es) |
PL (1) | PL2262785T3 (es) |
PT (1) | PT2262785E (es) |
SI (1) | SI2262785T1 (es) |
UA (1) | UA104140C2 (es) |
WO (1) | WO2009127321A1 (es) |
ZA (1) | ZA201008243B (es) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1976828T1 (sl) | 2005-12-29 | 2017-07-31 | Celtaxsys, Inc. | Diaminski derivati kot inhibitorji levkotrien A4 hidrolaze |
EP2110374A1 (en) * | 2008-04-18 | 2009-10-21 | Merck Sante | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators |
WO2010104194A1 (en) | 2009-03-10 | 2010-09-16 | Takeda Pharmaceutical Company Limited | Benzofuran derivatives |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
JP2013525489A (ja) | 2010-05-06 | 2013-06-20 | ブリストル−マイヤーズ スクイブ カンパニー | Gpr119修飾因子としての二環式ヘテロアリール類似体 |
EP2566862B1 (en) | 2010-05-06 | 2015-09-16 | Bristol-Myers Squibb Company | Benzofuranyl analogues as gpr119 modulators |
TW201204733A (en) | 2010-06-25 | 2012-02-01 | Kowa Co | Novel condensed pyridine or condensed pyrimidine derivative, and medicinal agent comprising same |
EP2655362A1 (en) | 2010-12-22 | 2013-10-30 | Abbvie Inc. | Hepatitis c inhibitors and uses thereof |
EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
WO2013037482A1 (en) | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
WO2014006637A2 (en) * | 2012-07-02 | 2014-01-09 | Symed Labs Limited | Improved process for preparing benzofuran-2-carboxamide derivatives |
CN102993186B (zh) * | 2012-12-20 | 2015-11-18 | 北京海步国际医药科技发展有限公司 | 一种新型的哌嗪衍生物 |
ES2864862T3 (es) | 2013-03-12 | 2021-10-14 | Celltaxis Llc | Métodos de inhibición de la leucotrieno A4 hidrolasa |
WO2014152536A2 (en) | 2013-03-14 | 2014-09-25 | Celtaxsys, Inc. | Inhibitors of leukotriene a4 hydrolase |
AU2014239567B2 (en) | 2013-03-14 | 2017-12-14 | Celtaxsys, Inc. | Inhibitors of leukotriene A4 hydrolase |
RU2696559C2 (ru) | 2013-03-14 | 2019-08-05 | Селтакссис, Инк. | Ингибиторы лейкотриен а4-гидролазы |
AU2014320463B2 (en) | 2013-09-11 | 2018-08-02 | Centre National De La Recherche Scientifique (Cnrs) | Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection |
MA40814A1 (fr) | 2015-02-06 | 2019-08-30 | Intercept Pharmaceuticals Inc | Compositions pharmaceutiques pour thérapie combinée |
CN107427527B (zh) | 2015-03-31 | 2021-01-26 | 英安塔制药有限公司 | 作为fxr/tgr5激动剂的胆汁酸衍生物及其使用方法 |
KR20170132879A (ko) | 2015-04-07 | 2017-12-04 | 인터셉트 파마슈티컬즈, 인크. | 조합 요법을 위한 약제학적 조성물 |
CN104926804B (zh) * | 2015-06-04 | 2019-01-25 | 天津渤海职业技术学院 | 一类具有抗肿瘤作用的化合物、其制备方法和用途 |
CA2968836A1 (en) | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
ES2921432T3 (es) | 2016-06-13 | 2022-08-25 | Gilead Sciences Inc | Derivados de azetidina como moduladores de FXR (NR1H4) |
BR112019006651A2 (pt) | 2016-10-04 | 2019-07-02 | Enanta Pharm Inc | análogos de isoxazol como agonistas de fxr e métodos de uso do mesmo |
CN108017636A (zh) * | 2016-11-04 | 2018-05-11 | 合帕吉恩治疗公司 | 作为fxr调节剂的含氮杂环化合物 |
ES2927019T3 (es) | 2017-03-28 | 2022-11-02 | Gilead Sciences Inc | Combinaciones terapéuticas para el tratamiento de enfermedades hepáticas |
WO2018178260A1 (en) | 2017-03-30 | 2018-10-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses |
US10898484B2 (en) | 2018-05-31 | 2021-01-26 | Celltaxis, Llc | Method of reducing pulmonary exacerbations in respiratory disease patients |
DK3911647T3 (da) | 2019-01-15 | 2024-02-26 | Gilead Sciences Inc | Isoxazol-forbindelse som FXR-agonist og farmaceutiske sammensætninger, der omfatter en sådan |
CN113439078B (zh) | 2019-02-19 | 2024-04-23 | 吉利德科学公司 | Fxr激动剂的固体形式 |
WO2020231917A1 (en) | 2019-05-13 | 2020-11-19 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
JP2022536060A (ja) | 2019-05-30 | 2022-08-12 | インターセプト ファーマシューティカルズ, インコーポレイテッド | 胆汁鬱滞性肝疾患の処置で使用するためのfxrアゴニストおよびフィブラートを含む医薬組成物 |
MX2022000742A (es) | 2019-07-18 | 2022-02-14 | Enyo Pharma | Metodo para disminuir los efectos adversos del interferon. |
EP4090327A1 (en) | 2020-01-15 | 2022-11-23 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Use of fxr agonists for treating an infection by hepatitis d virus |
CN117202905A (zh) | 2021-01-14 | 2023-12-08 | 埃尼奥制药公司 | Fxr激动剂和ifn用于治疗hbv感染的协同效果 |
JP2024503861A (ja) * | 2021-01-14 | 2024-01-29 | ウエヌイグレックオ・ファーマ | 慢性腎疾患を処置する方法 |
KR20240009411A (ko) * | 2021-04-16 | 2024-01-22 | 베이징 베스트 패스웨이 매니지먼트 컨설팅 센터 (리미티드 파트너쉽) | Fxr 조절인자, 이의 제조 방법, 이의 약제학적 조성물 및 이의 용도 |
JP2024517181A (ja) | 2021-04-28 | 2024-04-19 | ウエヌイグレックオ・ファーマ | 組合せ治療としてfxrアゴニストを使用するtlr3アゴニストの効果の強い増強 |
CN113214200B (zh) * | 2021-05-26 | 2022-03-29 | 神隆医药(常熟)有限公司 | 一种以铜催化偶联反应制备维拉佐酮中间体的方法 |
WO2023283425A1 (en) | 2021-07-09 | 2023-01-12 | Plexium, Inc. | Aryl compounds and pharmaceutical compositions that modulate ikzf2 |
WO2023137135A1 (en) * | 2022-01-17 | 2023-07-20 | Hepagene Therapeutics (HK) Limited | Solid forms of a benzthiazole-piperazinyl-oxazole compound and methods of use thereof |
WO2024032530A1 (zh) * | 2022-08-11 | 2024-02-15 | 江苏恩华药业股份有限公司 | 芳杂环并环己烷基氨基烷基哌啶衍生物、制备方法及其用途 |
CN117430574B (zh) * | 2023-12-20 | 2024-03-22 | 潍坊医学院 | 一种苯并呋喃衍生物及其制备方法、用途 |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0006524A1 (de) * | 1978-06-22 | 1980-01-09 | Ciba-Geigy Ag | Neue Tetrahydropyridin- und Piperidinderivate und deren Säureadditionssalze, Verfahren zu deren Herstellung und solche enthaltende pharmazeutische Zusammensetzungen |
FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
US5292736A (en) | 1993-02-26 | 1994-03-08 | Sterling Winthrop Inc. | Morpholinoalkylindenes as antiglaucoma agents |
US5706833A (en) * | 1993-07-13 | 1998-01-13 | Daicel Chemical Industries, Ltd. | Tobacco filters and method of producing the same |
DE4333254A1 (de) * | 1993-09-30 | 1995-04-06 | Merck Patent Gmbh | Piperidine und Piperazine |
US5532237A (en) | 1995-02-15 | 1996-07-02 | Merck Frosst Canada, Inc. | Indole derivatives with affinity for the cannabinoid receptor |
IL117580A0 (en) | 1995-03-29 | 1996-07-23 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them |
DE19514567A1 (de) * | 1995-04-20 | 1996-10-24 | Merck Patent Gmbh | Benzofurane |
FR2741621B1 (fr) | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
WO1997028149A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
AR008789A1 (es) | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
AU5928898A (en) | 1997-01-24 | 1998-08-18 | Regents Of The University Of California, The | Use of fxr, pparalpha and lxralpha activators to restore barrier function, promote epidermal differentiation and inhibit proliferation |
WO1998041519A1 (en) | 1997-03-18 | 1998-09-24 | Smithkline Beecham Corporation | Novel cannabinoid receptor agonists |
AU749271B2 (en) | 1997-07-01 | 2002-06-20 | Agouron Pharmaceuticals, Inc. | Glucagon antagonists/inverse agonists |
US6613942B1 (en) | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
AU8127998A (en) | 1997-07-11 | 1999-02-08 | Japan Tobacco Inc. | Quinoline compounds and medicinal uses thereof |
AU742425B2 (en) | 1998-06-11 | 2002-01-03 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
DE19837627A1 (de) | 1998-08-19 | 2000-02-24 | Bayer Ag | Neue Aminosäureester von Arylsulfonamiden und Analoga |
WO2000042026A1 (en) | 1999-01-15 | 2000-07-20 | Novo Nordisk A/S | Non-peptide glp-1 agonists |
US6071955A (en) | 1999-02-25 | 2000-06-06 | The Regents Of The University Of California | FXR, PPARA and LXRA activators to treat acne/acneiform conditions |
WO2000058360A2 (en) | 1999-03-29 | 2000-10-05 | Uutech Limited | Analogs of gastric inhibitory peptide and their use for treatment of diabetes |
AU4055400A (en) | 1999-04-02 | 2000-10-23 | Neurogen Corporation | Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics |
CA2373892A1 (en) | 1999-05-17 | 2000-11-23 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
JP2003505435A (ja) | 1999-06-04 | 2003-02-12 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン−4受容体ゴニストとしての置換ピペリジン |
DE19932314A1 (de) * | 1999-07-10 | 2001-01-11 | Merck Patent Gmbh | Benzofuranderivate |
TWI279402B (en) | 1999-08-20 | 2007-04-21 | Banyu Pharma Co Ltd | Spiro compounds having NPY antagonistic activities and agents containing the same |
RU2269354C2 (ru) | 1999-09-28 | 2006-02-10 | Байер Корпорейшн | Агонисты рецептора-3(r3) пептида-активатора гипофизарной аденилатциклазы(расар) и способы их фармакологического применения |
DE19958496A1 (de) * | 1999-12-04 | 2001-06-07 | Merck Patent Gmbh | Verfahren zur Herstellung von 5-(1-Piperazinyl)-benzofuran-2-carboxamid durch Übergangsmetallkatalysierte Aminierung |
AU4929601A (en) | 2000-03-23 | 2001-10-03 | Merck & Co Inc | Substituted piperidines as melanocortin receptor agonists |
EP1268000A4 (en) | 2000-03-23 | 2004-12-29 | Merck & Co Inc | SPIROPIPERID DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS |
WO2001082917A2 (en) | 2000-05-03 | 2001-11-08 | Tularik Inc. | Treatment of hypertriglyceridemia and other conditions using lxr modulators |
SK10802003A3 (sk) | 2001-02-02 | 2004-05-04 | Takeda Chemical Industries, Ltd. | Kondenzovaná heterocyklická zlúčenina, jej použitie a jej farmaceutický prípravok |
CN1633297A (zh) | 2001-02-28 | 2005-06-29 | 麦克公司 | 作为黑皮质素-4受体激动剂的酰化哌啶衍生物 |
DE10112151A1 (de) * | 2001-03-14 | 2002-09-19 | Merck Patent Gmbh | Substituierte Benzofuran-2-carbonsäureamide |
CZ2003698A3 (cs) | 2001-03-22 | 2003-06-18 | Solvay Pharmaceuticals B. V. | 4,5-Dihydro-1H-pyrazolové deriváty mající CB1-antagonistickou účinnost |
US6573287B2 (en) | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
FR2824825B1 (fr) | 2001-05-15 | 2005-05-06 | Servier Lab | Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
AU2002344820B2 (en) | 2001-06-20 | 2006-12-14 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
US7253172B2 (en) | 2001-06-20 | 2007-08-07 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
US6674272B2 (en) | 2001-06-21 | 2004-01-06 | Champion Microelectronic Corp. | Current limiting technique for a switching power converter |
JP4357293B2 (ja) | 2001-06-27 | 2009-11-04 | スミスクライン ビーチャム コーポレーション | ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類 |
DE60223920T2 (de) | 2001-06-27 | 2008-11-13 | Smithkline Beecham Corp. | Pyrrolidine als dipeptidyl-peptidase-inhibitoren |
WO2003002531A2 (en) | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
WO2003002593A2 (en) | 2001-06-27 | 2003-01-09 | Probiodrug Ag | Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis |
ATE388951T1 (de) | 2001-07-03 | 2008-03-15 | Novo Nordisk As | Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes |
UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
AU2002319627A1 (en) | 2001-07-20 | 2003-03-03 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
US6977264B2 (en) | 2001-07-25 | 2005-12-20 | Amgen Inc. | Substituted piperidines and methods of use |
KR20020082826A (ko) * | 2002-10-12 | 2002-10-31 | 박선희 | 한약재를 이용한 기능성피자의 제조방법 |
DE10326939A1 (de) * | 2003-06-16 | 2005-01-05 | Merck Patent Gmbh | Indol-Derivate |
DE10326940A1 (de) * | 2003-06-16 | 2005-01-05 | Merck Patent Gmbh | Indol-Derivate |
JP2009519290A (ja) * | 2005-12-15 | 2009-05-14 | エフ.ホフマン−ラ ロシュ アーゲー | ピロロ[2,3−c]ピリジン誘導体 |
EP1963331A1 (en) | 2005-12-15 | 2008-09-03 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
EP2110374A1 (en) * | 2008-04-18 | 2009-10-21 | Merck Sante | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators |
-
2008
- 2008-04-18 EP EP08300183A patent/EP2110374A1/en not_active Withdrawn
-
2009
- 2009-03-30 US US12/988,147 patent/US8575161B2/en active Active
- 2009-03-30 PL PL09731855T patent/PL2262785T3/pl unknown
- 2009-03-30 EP EP09731855.4A patent/EP2262785B1/en active Active
- 2009-03-30 MX MX2010011292A patent/MX2010011292A/es active IP Right Grant
- 2009-03-30 WO PCT/EP2009/002297 patent/WO2009127321A1/en active Application Filing
- 2009-03-30 BR BRPI0911243A patent/BRPI0911243B8/pt active IP Right Grant
- 2009-03-30 EA EA201001647A patent/EA020454B1/ru not_active IP Right Cessation
- 2009-03-30 CN CN2009801123063A patent/CN101990535B/zh active Active
- 2009-03-30 AU AU2009238015A patent/AU2009238015B2/en active Active
- 2009-03-30 DK DK09731855.4T patent/DK2262785T3/en active
- 2009-03-30 NZ NZ589327A patent/NZ589327A/en unknown
- 2009-03-30 SI SI200931168T patent/SI2262785T1/sl unknown
- 2009-03-30 ES ES09731855T patent/ES2531006T3/es active Active
- 2009-03-30 KR KR1020107025632A patent/KR101662853B1/ko active IP Right Grant
- 2009-03-30 JP JP2011504343A patent/JP5616326B2/ja active Active
- 2009-03-30 PT PT97318554T patent/PT2262785E/pt unknown
- 2009-03-30 CA CA2721591A patent/CA2721591C/en active Active
- 2009-03-30 MY MYPI2010004832A patent/MY156530A/en unknown
- 2009-03-30 UA UAA201013540A patent/UA104140C2/ru unknown
- 2009-04-17 AR ARP090101358A patent/AR071207A1/es active IP Right Grant
-
2010
- 2010-09-21 IL IL208322A patent/IL208322A/en active IP Right Grant
- 2010-10-15 CO CO10128317A patent/CO6311099A2/es active IP Right Grant
- 2010-11-17 ZA ZA2010/08243A patent/ZA201008243B/en unknown
- 2010-11-17 EC EC2010010615A patent/ECSP10010615A/es unknown
-
2011
- 2011-09-22 HK HK11109999.9A patent/HK1155741A1/xx unknown
-
2014
- 2014-07-18 JP JP2014147921A patent/JP5997730B2/ja active Active
-
2015
- 2015-03-19 HR HRP20150319TT patent/HRP20150319T1/hr unknown
- 2015-04-09 CY CY20151100343T patent/CY1116333T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2531006T3 (es) | Derivados de benzofurano como moduladores de FXR | |
CY1119515T1 (el) | Οξαζολο υποκατεστημενα ινδαζολια ως αναστολεις ρι3-κινασης | |
EA201790715A1 (ru) | Новые соединения | |
EA201490922A1 (ru) | ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ | |
EA201291394A1 (ru) | Твердые композиции | |
EA201590292A1 (ru) | Соединения, которые являются sip-модулирующими агентами и/или atx-модулирующими агентами | |
EA201100311A1 (ru) | Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы | |
UY34261A (es) | Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]-2-alcoxi-2-ciclil-etil}-1h-[1,2,4]triazol sustituidos | |
UY34259A (es) | Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]-2-alcoxi-3-metil-butil}-1h-[1,2,4]triazol sustituidos | |
EA201101396A1 (ru) | Ингибиторы аутотаксина | |
CR10955A (es) | Nuevo procedimiento de sintesis de la agomelatina | |
CY1112595T1 (el) | Αμιδοφαινοξυινδαζολια χρησιμα ως αναστολεις του c-met | |
CR20140468A (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
UY31986A (es) | Derivados n- sustituídos de la 2-metil-propionamida;{1-[5-sustiuido-4-sustituido-tiazol-2-il-carbamoil]-1-metil-etil} amidas de ácidos carboxílicos sustituidos, derivados farmacéuticamente aceptables de los mismos, composiciones y aplicaciones. | |
CO6690755A2 (es) | Heteroarilos como inhibidores de p13k | |
NZ702715A (en) | Pyrimidinyl tyrosine kinase inhibitors | |
CR10960A (es) | Nuevo procedimiento de sintesis de la agomelatina | |
CL2009000503A1 (es) | Proceso de preparacion de compuestos derivados de acido 2-amino-5-cianobenzoico-3-sustituidos o 1h-pirazol-5-carboxamida. | |
CU24398B1 (es) | 3-(piperidin,pirrol o azetidin)-indoles sustituidos útiles como inhibidores rorc2 | |
EA201291151A1 (ru) | Жидкие композиции рупатадина фумарата | |
DK3227273T3 (da) | Sammensætninger, som omfatter 2-((1-(2(4-fluorphenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-on, til behanlding af skizofreni | |
PE20130810A1 (es) | Compuestos de tetrahidrofuranilo disustituidos como antagonistas del receptor b1 de bradiquinina | |
BR112017017317A2 (pt) | Ácido (2s,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-4- (etoxioxalilamino)-2-hidroximetil-2-metilpentanóico como inibidor de neprilisina | |
EA201170074A1 (ru) | Изохинолиноновые производные в качестве антагонистов nk3 | |
ECSP099673A (es) | Formas sólidas de un inhibidor de cinasa raf |